Become–9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

BE-101 - Be Biopharma

Steven W. Pipe, MD1; Mark T Reding, MD2; Bryan Chin3; Karen Campbell3; Hanlan Liu, PhD3; Wing Yen Wong, MD3

Nov 22, 2024